Last reviewed · How we verify
LY3484356
At a glance
| Generic name | LY3484356 |
|---|---|
| Also known as | Imlunestrant |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PHASE1)
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (PHASE2)
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (PHASE3)
- A Study of Imlunestrant (LY3484356) in Female Healthy Participants (PHASE1)
- A Study of LY3484356 in Healthy Female Participants (PHASE1)
- A Study of [¹⁴C]-LY3484356 in Healthy Female Participants (PHASE1)
- A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (PHASE1)
- A Study of Imlunestrant (LY3484356) in Healthy Women (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3484356 CI brief — competitive landscape report
- LY3484356 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI